Pfizer Inc. logo

Pfizer Inc.

PFE

NYSEHealthcareDrug Manufacturers - General

Previous close

$28.07

+$0.28 · +1.01%

Aug 21, 4:02 PM ET

PFE company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

78

Undervalued

Momentum

36

Weakening

Sentiment

48

Mixed

Risk resilience

82

Low Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Headquarters
US
CEO
Albert Bourla
Listed since
Jun 1, 1972
Employees
75,000

Market position

Day range

Current $28.07

52-week range

Current $28.07

Open
$27.77
Previous close
$27.79
Volume
37.07M
0.92× average
Average volume
40.34M
Average daily volume
Market cap
159.98B USD
Beta
0.28
Market reference 1
50-day average
$25.361
+10.68% above average
200-day average
$25.9937
+7.99% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
207.77B USD
EV / EBITDA
13.76×
Earnings yield
5.49%
Free cash flow yield
6.41%

Profitability & efficiency

Return on equity
8.99%
Return on assets
3.73%
Return on invested capital
8.84%

Financial health

Current ratio
1.16×
Altman Z-score
2.09
Piotroski F-score
7 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends77%50%24%-3%Gross margin, FY2021: 57.67%Gross margin, FY2022: 61.89%Gross margin, FY2023: 50.95%Gross margin, FY2024: 65.77%Gross margin, FY2025: 70.33%Operating margin, FY2021: 25.58%Operating margin, FY2022: 37.43%Operating margin, FY2023: 8.89%Operating margin, FY2024: 25.91%Operating margin, FY2025: 24.67%Net margin, FY2021: 27.25%Net margin, FY2022: 31.26%Net margin, FY2023: 3.58%Net margin, FY2024: 12.60%Net margin, FY2025: 12.42%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 57.67%. Gross margin FY2022 61.89%. Gross margin FY2023 50.95%. Gross margin FY2024 65.77%. Gross margin FY2025 70.33%. Operating margin FY2021 25.58%. Operating margin FY2022 37.43%. Operating margin FY2023 8.89%. Operating margin FY2024 25.91%. Operating margin FY2025 24.67%. Net margin FY2021 27.25%. Net margin FY2022 31.26%. Net margin FY2023 3.58%. Net margin FY2024 12.60%. Net margin FY2025 12.42%.

Income trends

Revenue

62.58B USD-1.65%

Operating income

15.44B USD-6.35%

Net income

7.77B USD-3.12%
Income trends across reported periods110.15B USD70.87B USD31.59B USD−7.69B USDRevenue, FY2021: 81.29B USDRevenue, FY2022: 100.33B USDRevenue, FY2023: 59.55B USDRevenue, FY2024: 63.63B USDRevenue, FY2025: 62.58B USDOperating income, FY2021: 20.79B USDOperating income, FY2022: 37.55B USDOperating income, FY2023: 5.29B USDOperating income, FY2024: 16.48B USDOperating income, FY2025: 15.44B USDNet income, FY2021: 22.15B USDNet income, FY2022: 31.37B USDNet income, FY2023: 2.13B USDNet income, FY2024: 8.02B USDNet income, FY2025: 7.77B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 81.29B USD. Revenue FY2022 100.33B USD. Revenue FY2023 59.55B USD. Revenue FY2024 63.63B USD. Revenue FY2025 62.58B USD. Operating income FY2021 20.79B USD. Operating income FY2022 37.55B USD. Operating income FY2023 5.29B USD. Operating income FY2024 16.48B USD. Operating income FY2025 15.44B USD. Net income FY2021 22.15B USD. Net income FY2022 31.37B USD. Net income FY2023 2.13B USD. Net income FY2024 8.02B USD. Net income FY2025 7.77B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue62.58B USD63.63B USD59.55B USD100.33B USD81.29B USD
Cost of goods sold18.57B USD21.78B USD29.21B USD38.24B USD34.41B USD
Gross profit44.01B USD41.85B USD30.34B USD62.09B USD46.88B USD
Research and development11.98B USD10.74B USD10.58B USD11.43B USD13.83B USD
Selling, general, and administrative13.35B USD14.73B USD14.47B USD13.12B USD12.25B USD
Operating expenses28.58B USD25.36B USD25.05B USD24.54B USD26.08B USD
Interest income603M USD545M USD1.62B USD251M USD36M USD
Interest expense2.67B USD3.09B USD2.21B USD1.24B USD1.29B USD
Depreciation and amortization4.91B USD7.01B USD6.29B USD5.06B USD5.19B USD
Operating income15.44B USD16.48B USD5.29B USD37.55B USD20.79B USD
Net income7.77B USD8.02B USD2.13B USD31.37B USD22.15B USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
1.36
FY2025 · -3.55% year over year
Latest fiscal-year revenue
62.58B USD
FY2025 · -1.65% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend5.983.941.9-0.14FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend104.41B88.1B71.79B55.48BFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

39 ratings
Strong buy00%
Buy1538%
Hold2359%
Sell13%
Strong sell00%

Recent analyst actions

12 institutions

PFE news

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$1.72

2025 complete year+10.3% since 2021

2026 partial: $1.29

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jul 24, 2026

$0.43

Quarterly

Record Jul 24, 2026 · Payment Sep 1, 2026

Dividend

Ex-dividend May 8, 2026

$0.43

Quarterly

Record May 8, 2026 · Payment Jun 12, 2026

Dividend

Ex-dividend Jan 23, 2026

$0.43

Quarterly

Record Jan 23, 2026 · Payment Mar 6, 2026

Dividend

Ex-dividend Nov 7, 2025

$0.43

Quarterly

Record Nov 7, 2025 · Payment Dec 1, 2025

Dividend

Ex-dividend Jul 25, 2025

$0.43

Quarterly

Record Jul 25, 2025 · Payment Sep 2, 2025

Dividend

Ex-dividend May 9, 2025

$0.43

Quarterly

Record May 9, 2025 · Payment Jun 13, 2025

PFE peers

ETFs holding PFE

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research PFE

research.disclaimer